Erelzi<sup>®</sup> – biosimilar of etanercept in the treatment of rheumatic diseases and psoriasis (Resolution of the Expert Panel)

Erelzi<sup>®</sup> – biosimilar of etanercept in the treatment of rheumatic diseases and psoriasis (Resolution of the Expert Panel)

Introduction of biosimilars of biological disease-modifying antirheumatic drugs (bDMARs) into clinical practice has significantly expanded the availability of bDMARD therapy for a wide range of patients with chronic immuno-inflammatory diseases.In 2020, the first biosimilar etanercept Erelzi®, was r...

Full description

Bibliographic Details
Main Authors: V. I. Mazurov, A. M. Lila, T. V. Korotaeva
Format: Article
Language:Russian
Published: IMA-PRESS LLC 2021-08-01
Series:Современная ревматология
Subjects:
ревматические заболевания
псориаз
биоаналоги генно-инженерных биологических препаратов
этанерцепт
эрелзи<sup>®</sup>
Online Access:https://mrj.ima-press.net/mrj/article/view/1183

Similar Items

Similar Items